Oragenics is focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.
Type | Public | |
Founded | 1996 | |
HQ | Tampa, FL, US | Map |
Website | oragenics.com |
USD | |
---|---|
Revenue (Q1, 2022) | 15.1k |
Net income (Q1, 2022) | (6.0m) |
EBIT (Q1, 2022) | (6.1m) |
Market capitalization (26-Jul-2022) | 38.4m |
Closing stock price (26-Jul-2022) | 0.3 |
Cash (31-Mar-2022) | 21.4m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 347.6k | 350.4k | 380.5k | 256.4k | 176.4k | 167.7k | 253.4k | 214.7k | 303.8k | 201.0k | 363.8k | 242.0k | 329.8k | 262.3k | 15.1k | ||||||||||||||||
Cost of goods sold | 328.8k | 134.4k | 198.2k | 112.3k | 63.9k | 86.7k | 113.4k | 79.8k | 125.6k | 73.7k | 168.0k | 86.8k | 134.6k | 90.0k | |||||||||||||||||
Gross profit | 18.8k | 215.9k | 182.3k | 144.1k | 112.5k | 81.0k | 140.0k | 134.9k | 178.1k | 127.3k | 195.8k | 155.3k | 195.2k | 172.3k | |||||||||||||||||
Gross profit Margin, % | 5% | 62% | 48% | 56% | 64% | 48% | 55% | 63% | 59% | 63% | 54% | 64% | 59% | 66% |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 171.7k | 9.9m | 16.3m | 10.4m | 5.1m | 4.1m | 6.2m | 20.2m | 18.3m | 17.6m | 27.3m |
Accounts Receivable | 92.6k | 69.8k | 64.4k | 15.6k | 21.1k | 24.1m | 7.0k | ||||
Prepaid Expenses | 113.3k | 221.8k | 175.2k | 119.4k | 211.7k | 1.0m | 1.7m | 570.1k | 343.1k | 434.7k | |
Inventories | 475.6k | 124.2k | 288.4k | 439.2k | 321.5k | 141.1k |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 967.9k | 1.1m | 11.8m | 8.4m | 6.4m | 8.3m | 14.6m | 12.9m | 11.8m | 9.1m | 8.0m | 6.7m | 3.4m | 5.5m | 5.1m | 2.2m | 2.1m | 2.9m | 4.8m | 3.9m | 13.8m | 29.3m | 25.7m | 22.3m | 14.4m | 9.6m | 36.5m | 34.6m | 29.9m | 21.4m | ||
Accounts Receivable | 55.1k | 44.3k | 63.3k | 39.4k | 72.4k | 55.4k | 49.6k | 58.9k | 42.9k | 22.8k | 26.3k | 29.6k | 26.8k | 19.4k | 32.7k | |||||||||||||||||
Prepaid Expenses | 168.3k | 123.9k | 152.3k | 236.4k | 210.5k | 302.4k | 227.0k | 154.4k | 144.6k | 221.6k | 133.8k | 90.4k | 173.3k | 192.9k | 111.8k | 171.9k | 106.3k | 517.7k | 769.6k | 722.6k | 1.3m | 1.7m | 1.7m | 355.4k | 555.5k | 328.7k | 295.5k | 222.8k | 86.9k | 586.5k | 277.5k | |
Inventories | 500.6k | 465.5k | 363.0k | 353.8k | 279.9k | 117.3k | 303.0k | 223.3k | 265.9k | 239.0k | 263.9k | 377.0k | 364.1k | 299.3k | 241.5k |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (7.7m) | (13.1m) | (16.1m) | (5.8m) | (11.7m) | (7.0m) | (6.7m) | (9.9m) | (15.6m) | (26.4m) | (15.7m) |
Depreciation and Amortization | 79.5k | 75.2k | 76.5k | 27.7k | 71.2k | 75.0k | 65.8k | 30.1k | 62.6k | 51.7k | 41.2k |
Inventories | (209.0k) | 351.4k | (164.2k) | (150.8k) | 117.7k | ||||||
Accounts Payable | 225.3k | (57.5k) | (234.5k) | (199.7k) | 331.1k | 446.0k | 525.8k | 225.3k | 498.1k | (603.7k) | 10.6k |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (3.9m) | (5.7m) | (1.6m) | (8.5m) | (11.1m) | (1.6m) | (3.7m) | (13.0m) | (1.6m) | (3.5m) | (4.6m) | (1.3m) | (7.6m) | (9.5m) | (2.1m) | (2.4m) | (4.3m) | (2.0m) | (3.2m) | (5.3m) | (2.1m) | (4.4m) | (7.2m) | (3.3m) | (8.1m) | (12.0m) | (5.2m) | (17.5m) | (5.2m) | (9.0m) | (13.4m) | (6.0m) |
Depreciation and Amortization | 40.1k | 60.1k | 19.6k | 37.2k | 55.8k | 21.0k | 42.1k | 64.0k | 6.5k | 13.3k | 20.1k | 13.9k | 32.5k | 52.5k | 18.3k | 36.5k | 55.4k | 18.0k | 35.7k | 53.3k | 7.7k | 11.0k | 18.4k | 12.9k | 26.2k | 44.3k | 13.1k | 26.0k | 12.7k | 25.2k | 34.8k | 8.5k |
Inventories | (233.9k) | (198.8k) | 112.6k | 121.8k | 195.6k | 6.9k | 61.2k | 140.9k | 22.5k | 49.4k | 24.5k | 62.2k | 75.1k | 139.9k | 80.0k | |||||||||||||||||
Accounts Payable | 96.4k | 29.0k | 11.7k | 1.7k | (104.6k) | (75.3k) | 64.9k | (280.4k) | (102.6k) | (206.7k) | (305.6k) | (200.9k) | (161.5k) | 51.6k | 17.0k | (137.5k) | (44.8k) | (174.6k) | (216.1k) | 317.2k | 293.4k | 719.1k | 548.5k | 931.8k | 697.7k | 851.4k | 245.3k | (484.2k) | (364.3k) | 993.3k | 586.2k | 146.5k |
USD | Q2, 2011 |
---|---|
Financial Leverage | -0.3 x |
Oragenics has 46 Twitter Followers. The number of followers has increased 2.8% month over month and increased 2.4% quarter over quarter
When was Oragenics founded?
Oragenics was founded in 1996.
Who are Oragenics key executives?
Oragenics's key executives are Charles L. Pope, Michael Sullivan and Alan Dunton.
How many employees does Oragenics have?
Oragenics has 7 employees.
What is Oragenics revenue?
Latest Oragenics annual revenue is $87 k.
What is Oragenics revenue per employee?
Latest Oragenics revenue per employee is $12.4 k.
Who are Oragenics competitors?
Competitors of Oragenics include Genprex, Izun Pharmaceuticals and Bionnovation.
Where is Oragenics headquarters?
Oragenics headquarters is located at 4902 Eisenhower Blvd N #125, Tampa.
Where are Oragenics offices?
Oragenics has an office in Tampa.
How many offices does Oragenics have?
Oragenics has 1 office.
Receive alerts for 300+ data fields across thousands of companies